Accuracy of diagnostic tests in multiple sclerosis - a systematic review

Acta Neurologica Scandinavica

Volumn 124, Issue 3, 2011, Pages 151-164

  Schaffler N ^a   Kopke S ^b   Winkler, L ^a   Schippling, S ^a   Inglese, M ^c   Fischer, K ^a   Heesen, C ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b UNIVERSITY OF HAMBURG   (Germany)

^c NEW YORK UNIVERSITY   (United States)

Author keywords

Cerebrospinal fluid; Evoked potentials; Magnetic resonance imaging; Multiple sclerosis diagnosis; Systematic review; Test accuracy

Indexed keywords

CEREBROSPINAL FLUID ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; EVOKED RESPONSE; HUMAN; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; RELAPSE; REMISSION; REVIEW; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW;

ELECTRODIAGNOSIS; HUMANS; MAGNETIC RESONANCE IMAGING; MULTIPLE SCLEROSIS; OLIGOCLONAL BANDS; PREDICTIVE VALUE OF TESTS; SENSITIVITY AND SPECIFICITY;

EID: 79961192425     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/j.1600-0404.2010.01454.x     Document Type: Review

References (83)

1. Mcdonald WI, Compston A, Edan G et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001;50:121-7.
2. Polman CH, Reingold SC, Edan G et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol 2005;58:840-6.
3. Comi G, Filippi M, Barkhof F et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 2001;357:1576-82.
4. Kappos L, Polman CH, Freedman MS et al. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 2006;67:1242-9.
5. Jacobs LD, Beck RW, Simon JH et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med 2000;343:898-904.
6. Goodin DS. The causal cascade to multiple sclerosis: a model for MS pathogenesis. PLoS ONE 2009;4:e4565.
7. Freedman MS. 'Time is brain' also in multiple sclerosis. Mult Scler 2009;15:1133-4.
8. Compston A, Coles A. Multiple sclerosis. Lancet 2008;372:1502-17.
9. Schumacker GA, Beebe G, Kibler RF et al. Problems of experimental trials of therapy in multiple sclerosis: report by the panel on the evaluation of experimental trials of therapy in multiple sclerosis. Ann N Y Acad Sci 1965;122:552-68.
10. Mcalpine D, Lumsden CE, Acheson ED. Multiple sclerosis. A reappraisal. London: Churchill Livingstone, 1972; 83-307.
11. Mcdonald WI, Halliday AM. Diagnosis and classification of multiple sclerosis. Br Med Bull 1977;33:4-9.
12. Poser CM, Paty DW, Scheinberg L et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983;13:227-31.
13. Barkhof F, Filippi M, Miller DH et al. Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain 1997;120(Pt 11):2059-69.
14. Tintoré M, Rovira A, Martinez MJ et al. Isolated demyelinating syndromes: comparison of different MR imaging criteria to predict conversion to clinically definite multiple sclerosis. AJNR Am J Neuroradiol 2000;21: 702-6.
15. Poser CM, Brinar VV. Diagnostic criteria for multiple sclerosis: an historical review. Clin Neurol Neurosurg 2004;106:147-58.
16. Charil A, Yousry TA, Rovaris M et al. MRI and the diagnosis of multiple sclerosis: expanding the concept of "no better explanation". Lancet Neurol 2006;5:841-52.
17. Miller DH, Weinshenker BG, Filippi M et al. Differential diagnosis of suspected multiple sclerosis: a consensus approach. Mult Scler 2008;14:1157-74.
18. Whiting P, Harbord R, Main C et al. Accuracy of magnetic resonance imaging for the diagnosis of multiple sclerosis: systematic review. BMJ 2006;332:875-84.
19. Halliday AM, Mcdonald WI, Mushin J. Delayed visual evoked response in optic neuritis. Lancet 1972;1:982-5.
20. Tourtellotte WW, Parker JA. Multiple sclerosis: correlation between immunoglobulin-G in cerebrospinal fluid and brain. Science 1966;154:1044-5.
21. Felgenhauer K, Schadlich HJ, Nekic M, Ackermann R. Cerebrospinal fluid virus antibodies. A diagnostic indicator for multiple sclerosis? J Neurol Sci 1985;71:291-9.
22. Langer-Gould A, Popat RA, Huang SM et al. Clinical and demographic predictors of long-term disability in patients with relapsing-remitting multiple sclerosis: a systematic review. Arch Neurol 2006;63:1686-91.
23. Whiting PF, Weswood ME, Rutjes AW, Reitsma JB, Bossuyt PN, Kleijnen J. Evaluation of QUADAS, a tool for the quality assessment of diagnostic accuracy studies. BMC Med Res Methodol 2006;6:9.
24. Deeks JJ. Systematic reviews in health care: systematic reviews of evaluations of diagnostic and screening tests. BMJ 2001;323:157-62.
25. Haines TP, Hill K, Walsh W, Osborne R. Design-related bias in hospital fall risk screening tool predictive accuracy evaluations: systematic review and meta-analysis. J Gerontol A Biol Sci Med Sci 2007;62:664-72.
26. Whiting P, Rutjes AW, Dinnes J, Reitsma J, Bossuyt PM, Kleijnen J. Development and validation of methods for assessing the quality of diagnostic accuracy studies. Health Technol Assess 2004; 8:iii, 1-234.
27. Fazekas F, Offenbacher H, Fuchs S et al. Criteria for an increased specificity of MRI interpretation in elderly subjects with suspected multiple sclerosis. Neurology 1988;38:1822-5.
28. Paty DW, Oger JJ, Kastrukoff LF et al. MRI in the diagnosis of MS: a prospective study with comparison of clinical evaluation, evoked potentials, oligoclonal banding, and CT. Neurology 1988;38:180-5.
29. Swanton JK, Fernando K, Dalton CM et al. Modification of MRI criteria for multiple sclerosis in patients with clinically isolated syndromes. J Neurol Neurosurg Psychiatry 2006;77:830-3.
30. Rovira A, Swanton J, Tintore M et al. A single, early magnetic resonance imaging study in the diagnosis of multiple sclerosis. Arch Neurol 2009;66:587-92.
31. Korteweg T, Tintore M, Uitdehaag BM et al. A search for new MRI criteria for dissemination in space in subjects with a clinically isolated syndrome. Eur Radiol 2009;19:2244-8.
32. Minneboo A, Barkhof F, Polman CH, Uitdehaag BM, Knol DL, Castelijns JA. Infratentorial lesions predict long-term disability in patients with initial findings suggestive of multiple sclerosis. Arch Neurol 2004;61:217-21.
33. Dalton CM, Brex PA, Miszkiel KA et al. New T2 lesions enable an earlier diagnosis of multiple sclerosis in clinically isolated syndromes. Ann Neurol 2003;53:673-6.
34. Dalton CM, Brex PA, Miszkiel KA et al. Spinal cord MRI in clinically isolated optic neuritis. J Neurol Neurosurg Psychiatry 2003;74:1577-80.
35. Fisniku LK, Brex PA, Altmann DR et al. Disability and T2MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis. Brain 2008;131:808-17.
36. Swanton JK, Fernando KT, Dalton CM et al. Early MRI in optic neuritis: the risk for clinically definite multiple sclerosis. Mult Scler. 2010;16:156-65.
37. Sastre-Garriga J, Tintore M, Rovira A et al. Conversion to multiple sclerosis after a clinically isolated syndrome of the brainstem: cranial magnetic resonance imaging, cerebrospinal fluid and neurophysiological findings. Mult Scler 2003;9:39-43.
38. Sastre-Garriga J, Tintore M, Rovira A et al. Specificity of Barkhof criteria in predicting conversion to multiple sclerosis when applied to clinically isolated brainstem syndromes. Arch Neurol 2004;61:222-4.
39. Tintoré M, Rovira A, Rio J et al. Baseline MRI predicts future attacks and disability in clinically isolated syndromes. Neurology 2006;67:968-72.
40. Korteweg T, Tintore M, Uitdehaag B et al. MRI criteria for dissemination in space in patients with clinically isolated syndromes: a multicentre follow-up study. Lancet Neurol 2006;5:221-7.
41. Swanton JK, Rovira A, Tintore M et al. MRI criteria for multiple sclerosis in patients presenting with clinically isolated syndromes: a multicentre retrospective study. Lancet Neurol 2007;6:677-86.
42. Paolino E, Fainardi E, Ruppi P et al. A prospective study on the predictive value of CSF oligoclonal bands and MRI in acute isolated neurological syndromes for subsequent progression to multiple sclerosis. J Neurol Neurosurg Psychiatry 1996;60:572-5.
43. Filippini G, Comi GC, Cosi V et al. Sensitivities and predictive values of paraclinical tests for diagnosing multiple sclerosis. J Neurol 1994;241:132-7.
44. Jacobs LD, Kaba SE, Miller CM, Priore RL, Brownscheidle CM. Correlation of clinical, magnetic resonance imaging, and cerebrospinal fluid findings in optic neuritis. Ann Neurol 1997;41:392-8.
45. Beck RW, Trobe JD, Moke PS et al. High- and low-risk profiles for the development of multiple sclerosis within 10years after optic neuritis: experience of the optic neuritis treatment trial. Arch Ophthalmol 2003;121:944-9.
46. Masjuan J, Alvarez-Cermeno JC, Garcia-Barragan N et al. Clinically isolated syndromes: a new oligoclonal band test accurately predicts conversion to MS. Neurology 2006;66:576-8.
47. Rocca MA, Agosta F, Sormani MP et al. A three-year, multi-parametric MRI study in patients at presentation with CIS. J Neurol 2008;255:683-91.
48. Jafari N, Kreft KL, Flach HZ, Janssens AC, Hintzen RQ. Callosal lesion predicts future attacks after clinically isolated syndrome. Neurology 2009;73:1837-41.
49. Nielsen JM, Pohl C, Polman CH et al. MRI characteristics are predictive for CDMS in monofocal, but not in multifocal patients with a clinically isolated syndrome. BMC Neurol 2009;9:19.
50. Moraal B, Pohl C, Uitdehaag BM et al. Magnetic resonance imaging predictors of conversion to multiple sclerosis in the BENEFIT study. Arch Neurol 2009;66:1345-52.
51. Lo CP, Kao HW, Chen SY et al. Prediction of conversion from clinically isolated syndrome to clinically definite multiple sclerosis according to baseline MRI findings: comparison of revised McDonald criteria and Swanton modified criteria. J Neurol Neurosurg Psychiatry 2009;80:1107-9.
52. Chausson N, Olindo S, Signate A, Smadja D, Cabre P. Evaluation of the 2005 McDonald MRI criteria for dissemination in space in Afro-Caribbean patients with clinically isolated syndromes. Eur J Neurol 2009;16:1191-6.
53. Diaz-Sanchez M, Mayra Gomez-Moreno S, Asuncion Morales-Otal M, Ramos-Gonzalez A, Benito-Leon J. Accuracy of MRI criteria for dissemination in space for the diagnosis of multiple sclerosis in patients with clinically isolated syndromes. Mult Scler 2010;16:576-80.
54. Moulin D, Paty DW, Ebers GC. The predictive value of cerebrospinal fluid electrophoresis in 'possible' multiple sclerosis. Brain 1983;106(Pt 4):809-16.
55. Corridori F, Salmaggi A, Bortolami C et al. Prognostic value of cerebrospinal fluid electrophoresis in optic neuritis and suspected multiple sclerosis. Ital J Neurol Sci 1987;6:77-80.
56. Cole SR, Beck RW, Moke PS, Kaufman DI, Tourtellotte WW. The predictive value of CSF oligoclonal banding for MS 5years after optic neuritis. Optic Neuritis Study Group. Neurology 1998;51:885-7.
57. Nilsson P, Larsson EM, Maly-Sundgren P, Perfekt R, Sandberg-Wollheim M. Predicting the outcome of optic neuritis: evaluation of risk factors after 30years of follow-up. J Neurol 2005;252:396-402.
58. Lee KH, Hashimoto SA, Hooge JP et al. Magnetic resonance imaging of the head in the diagnosis of multiple sclerosis: a prospective 2-year follow-up with comparison of clinical evaluation, evoked potentials, oligoclonal banding, and CT. Neurology 1991;41:657-60.
59. Jin YP, Pedro-Cuesta J, Huang YH, Soderstrom M. Predicting multiple sclerosis at optic neuritis onset. Mult Scler 2003;9:135-41.
60. Rolak LA, Beck RW, Paty DW, Tourtellotte WW, Whitaker JN, Rudick RA. Cerebrospinal fluid in acute optic neuritis: experience of the optic neuritis treatment trial. Neurology 1996;46:368-72.
61. Soderstrom M, Ya-Ping J, Hillert J, Link H. Optic neuritis: prognosis for multiple sclerosis from MRI, CSF, and HLA findings. Neurology 1998;50:708-14.
62. Ghezzi A, Martinelli V, Torri V et al. Long-term follow-up of isolated optic neuritis: the risk of developing multiple sclerosis, its outcome, and the prognostic role of paraclinical tests. J Neurol 1999;246:770-5.
63. Tintoré M, Rovira A, Rio J et al. New diagnostic criteria for multiple sclerosis: application in first demyelinating episode. Neurology 2003;60:27-30.
64. Villar LM, Garcia-Barragan N, Sadaba MC et al. Accuracy of CSF and MRI criteria for dissemination in space in the diagnosis of multiple sclerosis. J Neurol Sci 2008;266:34-7.
65. Tintoré M, Rovira A, Rio J et al. Do oligoclonal bands add information to MRI in first attacks of multiple sclerosis? Neurology 2008;70:1079-83.
66. Perumal J, Zabad R, Caon C et al. Acute transverse myelitis with normal brain MRI: long-term risk of MS. J Neurol 2008;255:89-93.
67. Zipoli V, Hakiki B, Portaccio E et al. The contribution of cerebrospinal fluid oligoclonal bands to the early diagnosis of multiple sclerosis. Mult Scler 2009;15:472-8.
68. Rojas JI, Patrucco L, Cristiano E. Oligoclonal bands and MRI in Clinically Isolated Syndromes: predicting conversion time to multiple sclerosis. J Neurol 2010;257:1188-91.
69. Pelayo R, Montalban X, Minoves T et al. Do multimodal evoked potentials add information to MRI in clinically isolated syndromes? Mult Scler 2010;16:55-61.
70. Freedman MS, Thompson EJ, Deisenhammer F et al. Recommended standard of cerebrospinal fluid analysis in the diagnosis of multiple sclerosis: a consensus statement. Arch Neurol 2005;62:865-70.
71. Gronseth GS, Ashman EJ. Practice parameter: the usefulness of evoked potentials in identifying clinically silent lesions in patients with suspected multiple sclerosis (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000;54:1720-5.
72. Leeflang MM, Deeks JJ, Gatsonis C, Bossuyt PM. Systematic reviews of diagnostic test accuracy. Ann Intern Med 2008;149:889-97.
73. Knottnerus JA, Van Weel C, Muris JW. Evaluation of diagnostic procedures. BMJ 2002;324:477-80.
74. O'connor PW, Tansay CM, Detsky AS, Mushlin AI, Kucharczyk W. The effect of spectrum bias on the utility of magnetic resonance imaging and evoked potentials in the diagnosis of suspected multiple sclerosis. Neurology 1996;47:140-4.
75. Neuhaus A, Güntner M, Morrissey SP. Risk factors for conversion to multiple sclerosis in patients with a clinically isolated syndrome, ECTIMS October 11, 2007; Abstr. 16.
76. Montalban X, Tintore M, Swanton J et al. MRI criteria for MS in patients with clinically isolated syndromes. Neurology 2010;74:427-34.
77. Kinkel RP, Kollman C, O'connor P et al. IM interferon beta-1a delays definite multiple sclerosis 5years after a first demyelinating event. Neurology 2006;66:678-84.
78. Kappos L, Freedman MS, Polman CH et al. Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. Lancet 2007;370:389-97.
79. Gluud C, Gluud LL. Evidence based diagnostics. BMJ 2005;330:724-6.
80. Windeler J. Prognosis - what does the clinician associate with this notion? Stat Med 2000;19:425-30.
81. Schunemann HJ, Oxman AD, Brozek J et al. Grading quality of evidence and strength of recommendations for diagnostic tests and strategies. BMJ 2008;336:1106-10.
82. General Medical Council. Consent: patients and doctors making decisions together. London: British General Medical Council, 2008;
83. Heesen C, Schäffler N, Kasper J, Mühlhauser I, Köpke S. Suspected multiple sclerosis - what to do? Evaluation of a patient information leaflet. Mult Scler 2009;15:1103-12.